SCHEMBL3524259

SCHEMBL3524259

CCOC(=O)CNC(=O)c1c(O)c(-c2ccccc2)cc2ncc(-c3ccccc3)nc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 2/20 0.52
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
HSD17B10 Q99714 1/20 0.44
HPGD P15428 2/20 0.42
LMNA P02545 3/20 0.42
SQOR Q9Y6N5 1/20 0.42
CASP1 P29466 1/20 0.41
ALDH1A1 P00352 4/20 0.40
CCR6 P51684 1/20 0.39
P2RY12 Q9H244 2/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PPID Q08752 1/20 0.38
ABL1 P00519 1/20 0.38
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3518821 0.92 EGLN3 (0.49) EGLN3NPC1RAB9AHSD17B10HPGD
SCHEMBL3756186 0.92 EGLN3 (0.50) EGLN3NPC1RAB9AHSD17B10HPGD
SCHEMBL3761475 0.90 NPC1 (0.45) EGLN3NPC1RAB9AHSD17B10HPGD
SCHEMBL3761491 0.89 EGLN3 (0.45) EGLN3NPC1RAB9AHSD17B10HPGD
SCHEMBL3522312 0.87 EGLN3 (0.67) EGLN3
SCHEMBL3756784 0.85 NPC1 (0.48) EGLN3NPC1RAB9AHSD17B10HPGD
SCHEMBL3524105 0.84 LMNA (0.49) EGLN3NPC1RAB9AHSD17B10HPGD
SCHEMBL3756004 0.83 EGLN3 (0.42) EGLN3NPC1RAB9AHSD17B10HPGD
SCHEMBL3760876 0.82 EGLN3 (0.54) EGLN3HSD17B10HPGDLMNASQOR
SCHEMBL3764754 0.82 LMNA (0.45) EGLN3NPC1RAB9AHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885NPC1 2674/4885RAB9A 3111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.